EPAS1 and nonpapillary renal cell carcinoma: These findings together suggest that HIF2α inhibitor is efficient for combating high-PVT1 or -HIF2α expression ccRCC by blocking the positive feedback regulatory loop between PVT1 and HIF2α (Fig. 6J).